Skip to main content
Premium Trial:

Request an Annual Quote

DiaGenic, Pfizer Sign Deal for Alzheimer's Biomarker Discovery

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian biotech DiaGenic said it will use its gene expression technology to identify biomarkers of early-stage Alzheimer's disease for Pfizer, under a deal announced today by DiaGenic.

The firms will conduct a study, expected to begin this month, to compare longitudinal changes in blood-based gene expression patterns in patients with stable mild cognitive impairment, progressive MCI, and Alzheimer's disease. They hope to identify gene expression patterns in patients who progress from MCI to Alzheimer's disease and with different stages of the disease.

Pfizer will receive a non-exclusive, worldwide license for use of DiaGenic's MCI test and Alzheimer's test in its R&D development programs.

Additional terms of the deal were not disclosed.

In a statement, Erik Christensen, CEO of Oslo, Norway-based DiaGenic, said the deal "is the first result of DiaGenic's refocused strategy on teaming up with large pharmaceutical companies to deliver new diagnostic tools."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more